Executive order on pharma benefits

Extracted Attributes

• Primary Goal

  Lower drug prices

• Primary Mechanism

  Most Favored Nation (MFN) status

• Debated Consequences

  Risk of stifling pharmaceutical R&D, necessity of reforming Pharmacy Benefit Managers (PBMs), increasing competition from China's pharmaceutical sector

• Related Policy Areas

  Domestic production of medicines, price transparency, enhanced competition, Medicare and Medicaid drug pricing, international importation, drug manufacturer competition

• Issuing Administration

  Donald Trump's administration

Timeline

• Purdue Frederick Company (later Purdue Pharma) was founded by John Purdue Gray. (Source: wikipedia)

  1892

• Purdue Frederick Company was sold to Arthur, Mortimer, and Raymond Sackler. (Source: wikipedia)

  1952

• Purdue Pharma paid one of the largest fines ever levied against a pharmaceutical firm for misleading the public about how addictive OxyContin was. (Source: wikipedia)

  2007

• Purdue Pharma filed for Chapter 11 bankruptcy protection in New York City. (Source: wikipedia)

  2019-09-15

• Purdue Pharma reached a settlement potentially worth US$8.3 billion, admitting to aiding doctors in dispensing medication without a legitimate medical purpose. Sackler family members also agreed to pay US$225 million. (Source: wikipedia)

  2020-10-21

• Purdue Pharma announced that it would rebrand itself as Knoa Pharma. (Source: wikipedia)

  2021-09

• As of this date, Purdue Pharma remained in Chapter 11 bankruptcy, pending a Department of Justice appeal to the United States Supreme Court. (Source: wikipedia)

  2023-08

Purdue Pharma

Purdue Pharma L.P., formerly the Purdue Frederick Company (1892–2019), was an American privately held pharmaceutical company founded by John Purdue Gray. It was sold to Arthur, Mortimer, and Raymond Sackler in 1952, and then owned principally by the Sackler family and their descendants. The company manufactured pain medicines such as hydromorphone, fentanyl, codeine, hydrocodone and oxycodone, also known by its brand name, OxyContin. The Sacklers developed aggressive marketing tactics persuading doctors to prescribe OxyContin in particular. Doctors were enticed with free trips to pain-management seminars (which were effectively all-expenses-paid vacations) and paid speaking engagements. Sales of their drugs soared, as did the number of people dying from overdoses. From 1999 to 2020, nearly 841,000 people died from drug overdoses in the United States, with prescription and illicit opioids responsible for 500,000 of those deaths. A series of lawsuits followed. In 2007, Purdue paid out one of the largest fines ever levied against a pharmaceutical firm for misleading the public about how addictive the drug OxyContin was compared to other pain medications. In response to the lawsuits, the company shifted its focus to abuse-deterrent formulations, but continued to market and sell opioids as late as 2019 and continued to be involved in lawsuits around the opioid epidemic in the United States. Purdue filed for Chapter 11 bankruptcy protection on September 15, 2019, in New York City. On October 21, 2020, it was reported that Purdue had reached a settlement potentially worth US$8.3 billion, admitting that it "knowingly and intentionally conspired and agreed with others to aid and abet" doctors dispensing medication "without a legitimate medical purpose." Members of the Sackler family would additionally pay US$225 million and the company would close. Some state attorneys general protested the plan. In March 2021, the United States House of Representatives introduced a bill that would stop the bankruptcy judge in the case from granting members of the Sackler family legal immunity during the bankruptcy proceedings. The House Judicial Committee referred it to the Subcommittee on Antitrust, Commercial, and Administrative Law in October 2021. The bill lapsed at the end of the 117th Congress in January 2023. In September 2021, Purdue Pharma announced that it would rebrand itself as Knoa Pharma. As of August, 2023, Purdue Pharma remains in chapter 11 bankruptcy, pending a Department of Justice appeal to the United States Supreme Court, of the United States Court of Appeals for the Second Circuit ruling that the bankruptcy proceedings may continue. The company's downfall was the subject of the 2021 Hulu miniseries Dopesick, the 2021 HBO film The Crime of the Century, the 2023 Netflix series Painkiller, and several documentaries and books. Purdue Pharma had no relation to Purdue University or the Purdue University College of Pharmacy, something Purdue University has made clear on multiple occasions to avoid association.

Web Search Results

• Executive order promotes domestic production of medicines, other ...

  The Trump administration May 5 issued two executive orders on pharmaceutical manufacturing and life-sciences research. The first executive order, "Regulatory Relief to Promote Domestic Production of Critical Medicines," directs the Commissioner of the Food and Drug Administration within 180 days to streamline and accelerate the development of domestic pharmaceutical manufacturing by eliminating unnecessary or duplicative regulations and improving inspection processes. The order similarly [...] directs the Administrator of the Environmental Protection Agency to update regulations and guidance for the inspection and approval of pharmaceutical manufacturing capacity and eliminate duplicative or unnecessary requirements. It also establishes the EPA as the lead agency for the permitting of pharmaceutical manufacturing facilities that require an Environmental Impact Statement and requires the agency to work with other agencies to expedite the review and approval of relevant permits. [...] American Hospital Association. Advancing Health in America American Hospital Association. Advancing Health in America ## Secondary Menu ## Breadcrumb # Executive order promotes domestic production of medicines, other executive actions aonl cta news white house

• Trump Administration Issues Drug Pricing Executive Order | Mintz

  Mintz logo # Trump Administration Issues Drug Pricing Executive Order On April 15, 2025, President Trump issued an Executive Order instructing federal agencies to implement a variety of drug pricing reforms. The Executive Order addresses drug pricing from several different angles, including pharmacy benefit manager (PBM) competition and transparency, Medicare and Medicaid drug pricing, international importation, and drug manufacturer competition (Executive Order). [...] Improving upon the Inflation Reduction Act. The Executive Order directs the Secretary of Health and Human Services (HHS) to propose and seek comment on guidance for the Medicare Drug Price Negotiation Program (Negotiation Program). The stated purpose of the guidance is to “improve the transparency of the Negotiation Program, prioritize the selection of prescription drugs with high costs to the Medicare program, and minimize any negative impacts of the maximum fair price (MFP) on pharmaceutical [...] Focus on Pharmacy Benefit Manager Transparency

• ​Executive Order 14273 Summary: Pricing, Transparency, and ...

  To address price transparency, the EO directs the Secretary to conduct a survey to determine hospital acquisition costs for outpatient drugs (section 5), to provide recommendations to try to ensure the accuracy of drug rebates paid by manufacturers under the Medicaid program (section 6), and to propose regulations to increase transparency in the compensation structure for pharmacy benefit managers (PBMs) by employer-sponsored health plans (section 12). [...] In conclusion, the Executive Order signed by President Trump on 15 April 2025, titled “Lowering Drug Prices by Once Again Putting Americans First,” expresses an effort to address three policy areas of concern: price reduction, transparency in the pharmaceutical supply chain, and enhanced competition. The directives encompass a range of actions that are meant to bring cost savings for seniors and low-income individuals through targeted reforms to Medicare, the 340B program, and drug importation [...] 25 April 2025 ## ​Executive Order 14273 Summary: Pricing, Transparency, and Competition in the Pharmaceutical Industry Kiefer Ahn Dennis J. Campbell Share Splash of color On 15 April 2025, President Donald Trump signed an Executive Order (EO) titled “Lowering Drug Prices by Once Again Putting Americans First.”1 The stated purpose of the EO is to broaden access to pharmaceutical products through lower prices. In particular, three policy issues are highlighted: ## Pricing

• Fact Sheet: President Donald J. Trump Announces Actions to Put ...

  The Order directs the U.S. Trade Representative and Secretary of Commerce to take action to ensure foreign countries are not engaged in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States. The Order instructs the Administration to communicate price targets to pharmaceutical manufacturers to establish that America, the largest purchaser and funder of prescription drugs in the world, gets the best deal. [...] This Order builds on actions from President Trump’s first term to make progress on reducing price disparities at home and expands those efforts by including Medicaid in addition to Medicare. President Trump recently signed an Executive Order to take additional action to lower drug prices, including by providing massive discounts to low-income patients for lifesaving medicines, facilitating importation programs, and increasing the availability of generic and biosimilar medicines. [...] REDUCING DRUG PRICES FOR AMERICANS AND TAXPAYERS:Today, President Donald J. Trump signed an Executive Order to bring the prices Americans and taxpayers pay for prescription drugs in line with those paid by similar nations.

• Overview of President Trump's Executive Actions on Global Health

  This Executive Order will have immediate impacts via the ordered actions related to the three U.N. organizations specified, much as the impacts of the Jan. 20, 2025, Executive Order on theWorld Health Organization (WHO, which initiatedU.S.withdrawal from membership and halted U.S. funding) are already being seen. Beyond these, additional impacts of this Executive Order will be determined by the findings and recommendations of the international organizations and conventions review, particularly [...] particularly for HIV/AIDS, from the United States government. The executive order allows the heads of U.S. agencies to permit the provision of foreign aid or assistance under this order at their discretion. On February 10, the U.S. Embassy and Consulates in South Africa announcedthat PEPFAR would not be impacted by this Executive Order and could continue under the limited waiver already granted to the foreign aid funding freeze. No other exceptions have yet been announced. [...] The Secretary of State may waive the pause for specific programs.What Happens Next/Implications: Almost all global health programs are funded through foreign aid appropriations and are therefore subject to this order. The order temporarily freezes any new U.S. government spending (obligations or disbursements) through these programs, which could interrupt implementation of programs for which funds have not yet been obligated. It also calls for a 90-day review of all foreign aid programs. Key